Cardiopulmonary Endpoints: Why Heart and Lung Data Belong in the Same Conversation

Cardiopulmonary endpoints assess heart and lung function together rather than in isolation. Because the cardiac and respiratory systems share physiology and risk pathways, integrated assessment combining ECG, cardiac imaging, pulmonary function and exercise testing can reveal safety and efficacy signals that siloed cardiac or respiratory endpoints miss.

A patient in a COPD trial reports that they can no longer climb the stairs to their apartment. Their FEV1 has not changed. Their ECG at the last visit was unremarkable. Two datasets, both reassuring, and a patient who is unmistakably worse.

The explanation is usually that the limitation is not in either organ alone but in the system they form together. Oxygen has to be moved from air into blood and from blood into muscle, and a failure anywhere along that chain produces the same complaint. Trials that measure the heart and the lung separately are looking at two halves of one problem and hoping the answer appears in one of them.

What Cardiopulmonary Endpoints Are

Cardiopulmonary endpoints measure the integrated function of the cardiovascular and respiratory systems rather than either one on its own. They fall into three broad groups.

Structural and functional measures taken at rest: ECG, echocardiography or cardiac MRI on one side; spirometry, DLCO, oscillometry and lung imaging on the other. Integrated functional measures taken under load, principally cardiopulmonary exercise testing and field walking tests. And composite clinical outcomes in which cardiac and respiratory events are both counted, such as hospitalization for cardiorespiratory causes.

The distinguishing feature is not the number of tests. It is whether the results are interpreted against each other or filed in separate reports.

Why Heart and Lung Data Are Usually Siloed

The separation is organizational before it is scientific. Cardiac safety usually sits with one team and one provider, respiratory endpoints with another. The modalities differ, the reading conventions differ, the timelines differ, and the two datasets often arrive in different formats at different points in the study.

Protocol structure reinforces it. Cardiac assessments appear under safety, respiratory assessments under efficacy, and nothing in the document asks anyone to look at them together. By the time both datasets exist in the same database, the analysis plan has already decided they answer different questions.

The same fragmentation shows up inside respiratory measurement itself, where global lung metrics can flatten out regional change, an issue covered in our piece on regional imaging biomarkers. Cardiopulmonary siloing is that problem one level up.

The Case for Integrated Cardiopulmonary Assessment

Shared physiology and risk pathways

The two systems are mechanically coupled. Pulmonary vascular resistance determines right ventricular afterload, so chronic lung disease loads the right heart. Left-sided heart failure raises pulmonary venous pressure and produces restrictive physiology that looks respiratory on a spirometer. Hypoxemia drives tachycardia and pulmonary vasoconstriction. Systemic inflammation affects both.

Drug effects travel the same routes. A compound that raises heart rate changes the QT correction and the exercise response at once, which is one reason cardiac safety has become a lifecycle discipline rather than a single late-phase study. A pulmonary vasodilator has systemic hemodynamic consequences. Oncology agents with cardiotoxic potential often present first as reduced exercise tolerance rather than as a change in ejection fraction.

CPET and functional capacity (VO2, 6MWT)

Cardiopulmonary exercise testing is the only routine assessment that loads all of these systems simultaneously. It provides, as one recent review puts it, an integrated appraisal of cardiovascular, respiratory and metabolic responses to exertion. Peak VO2 reflects overall aerobic capacity; the VE/VCO2 slope reflects ventilatory efficiency. Reduced peak VO2 and an elevated VE/VCO2 slope are both associated with worse outcomes in heart failure, and abnormalities that appear only under load are invisible at rest.

The six-minute walk test is the pragmatic alternative, and it is more fragile than its simplicity suggests. The ERS/ATS technical standard on field walking tests reports intra-class correlation coefficients between 0.82 and 0.99 for the six-minute walking distance, which is excellent, but it also documents a pooled mean improvement of 26.3 m on a second test performed by the same patient. Standardized encouragement alone accounts for around 30.5 m. With a minimal important difference of roughly 30 m in chronic respiratory disease, a study that performs one baseline test and does not standardize encouragement can manufacture a treatment effect out of a learning curve.

This is why the standard recommends two tests when the measure is being used to detect change over time, on a flat, straight course of 30 m or more. In a multicenter trial, it is also why the walking corridor at each site is worth asking about before enrollment opens.

Reading imaging and ECG together

The most practical form of integration is interpretive rather than technological. A reduction in ejection fraction on echocardiography means something different when it appears alongside a new conduction abnormality on ECG and a fall in exercise capacity than it does in isolation. A rise in resting heart rate reads differently when lung imaging shows progressive fibrotic change.

None of that requires new equipment. It requires the cardiac and respiratory readings to reach the same reviewer, in the same timeframe, with enough context to be compared, which is squarely a question of how cardiac safety services are scoped at design stage.

Where It Matters Most

Heart failure. Dyspnea is the presenting symptom and the endpoint, and disentangling cardiac from pulmonary contributions is the entire clinical problem. CPET is standard for a reason.

Pulmonary hypertension. The disease is defined at the interface. Right ventricular function and pulmonary vascular resistance cannot be assessed meaningfully apart from each other.

COPD and severe asthma. Cardiovascular comorbidity is the rule rather than the exception in these populations, and inhaled therapies with systemic absorption carry cardiac considerations of their own.

Oncology cardiotoxicity. Anthracyclines, HER2-targeted agents and checkpoint inhibitors can affect cardiac structure and function. In patients with thoracic disease or prior radiotherapy, separating cardiac from pulmonary decline requires both datasets.

Integrating the two is straightforward when the same provider holds both. Banook has run cardiac safety as a core lab discipline since 1999, covering 12-lead ECG, Holter, blood pressure monitoring and cardiac imaging with QT analysis across QTcB, QTcF and QTcL, under the oversight of board-certified cardiologists. On the respiratory side, the integration of Fluidda brought more than twenty years of functional respiratory imaging into the group: low-dose high-resolution CT combined with computational fluid dynamics to produce patient-specific three-dimensional biomarkers of airway geometry, airflow, ventilation distribution and aerosol deposition, alongside standardized pulmonary function testing covering spirometry, FeNO, oscillometry and DLCO. Both data streams run on the same in-house platform, which is what makes reading them against each other an ordinary operation rather than a project.

👉 Review Banook full cardiac safety offering or talk to the team about a specific protocol

Frequently Asked Questions

What are cardiopulmonary endpoints?

Cardiopulmonary endpoints measure heart and lung function as a single system rather than separately. They combine resting cardiac assessments such as ECG and echocardiography with pulmonary function testing and lung imaging, and often include integrated functional measures such as cardiopulmonary exercise testing or the six-minute walk test.

Why assess heart and lung function together?

Because the two systems are mechanically and physiologically coupled. Pulmonary disease loads the right heart, left heart failure produces restrictive respiratory physiology, and hypoxemia affects both. A change in one system frequently presents as a symptom attributed to the other, so assessing them separately can leave a real signal invisible in each dataset.

What is CPET (cardiopulmonary exercise testing)?

CPET measures gas exchange and cardiovascular response during graded exercise, producing an integrated appraisal of cardiovascular, respiratory and metabolic function under load. Its principal variables are peak VO2, reflecting aerobic capacity, and the VE/VCO2 slope, reflecting ventilatory efficiency. Both carry prognostic weight in heart failure.

Which trials benefit from cardiopulmonary monitoring?

Heart failure and pulmonary hypertension programs, where the disease sits at the cardiopulmonary interface. COPD and severe asthma studies, where cardiovascular comorbidity is common. Oncology programs with cardiotoxic potential, particularly in patients with thoracic disease. And any study where exercise tolerance or dyspnea is an endpoint.

How are cardiac and respiratory data integrated?

Through a shared acquisition standard, a common data platform and, most importantly, a reading process that puts both datasets in front of the same reviewers within the same timeframe. Integration is interpretive before it is technical: the value comes from comparing findings, not from storing them together.